Hoshiai, Hiroshi
Seki, Yoshifumi
Kusumoto, Takeru
Kudou, Kentarou
Tanimoto, Masataka
Clinical trials referenced in this document:
Documents that mention this clinical trial
Relugolix for oral treatment of uterine leiomyomas: a dose-finding, randomized, controlled trial
https://doi.org/10.1186/s12905-021-01475-2
Funding for this research was provided by:
Takeda Pharmaceutical Company
Article History
Received: 18 March 2021
Accepted: 8 September 2021
First Online: 28 October 2021
Declarations
:
: The study was conducted in accordance with the principles outlined in the Declaration of Helsinki, the International Council for Harmonisation Guideline for Good Clinical Practice, and all applicable local regulatory requirements. All participants provided written informed consent. Ethical approval for the study, including the protocol and informed consent form, was obtained from the Institutional Review Board (IRB) at each study site: Chayamachi Ladies Clinic IRB, NPO Clinical Research Promotion Network Japan IRB, Jinsenkai Hanna Hospital IRB, Meiwa Hospital IRB, Shintokai Yokohama Minoru Clinic IRB, Ehime Prefectural Central Hospital IRB, International University of Health and Welfare-IRB, Hakataeki-higashi Clinic IRB, Chiba Kaihin Municipal Hospital IRB, Eiyukai Yasuda Hospital IRB, Sapporo Medical Association’s IRB, Kenporen Osaka Central Hospital IRB, Kansai Rosai Hospital IRB, Yamate Dermatological Clinic IRB, Tokushukai Group IRB, Fukui General Hospital IRB, Toyama Prefectural Central Hospital IRB, Oita Red Cross Hospital IRB, Japan Organization of Occupational Health and Safety Ehime Rosai Hospital IRB, Japan Organization of Occupational Health and Safety Chiba Rosai Hospital IRB, Aso Co., Iizuka Hospital IRB, Fukui Prefectural Hospital IRB, and Ogikubo Hospital IRB.
: Not applicable.
: Hiroshi Hoshiai has received consultancy fees from Takeda Pharmaceutical Company Limited, and Yoshifumi Seki, Takeru Kusumoto, Kentarou Kudou, and Masataka Tanimoto are current and past employees of Takeda Pharmaceutical Company Limited.